US20140179712A1 - Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide - Google Patents

Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide Download PDF

Info

Publication number
US20140179712A1
US20140179712A1 US14/108,595 US201314108595A US2014179712A1 US 20140179712 A1 US20140179712 A1 US 20140179712A1 US 201314108595 A US201314108595 A US 201314108595A US 2014179712 A1 US2014179712 A1 US 2014179712A1
Authority
US
United States
Prior art keywords
formula
further aspect
tablet
invention
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/108,595
Inventor
Noel Alan Weldon BAKER
Alpesh MISTRY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201261740520P priority Critical
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Priority to US14/108,595 priority patent/US20140179712A1/en
Assigned to ASTRAZENECA UK LIMITED reassignment ASTRAZENECA UK LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BAKER, Noel Alan Weldon, MISTRY, Alpesh
Assigned to ASTRAZENECA AB reassignment ASTRAZENECA AB ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ASTRAZENECA UK LIMITED
Publication of US20140179712A1 publication Critical patent/US20140179712A1/en
Application status is Abandoned legal-status Critical

Links